

References

1. Gibson-Helm M, McAllister V, Norman RJ, et al. BMJ rapid response 13th September 2017. <http://www.bmj.com/content/358/bmj.j3694/rr>
2. Copp T, Jansen J, Doust J, et al. Are expanding disease definitions unnecessarily labelling women with polycystic ovary syndrome? *Bmj* 2017;358:j3694.
3. Lizneva D, Suturina L, Walker W, et al. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. *Fertility and sterility* 2016.
4. Azziz R, Carmina E, Chen Z, et al. Polycystic ovary syndrome. *Nat Rev Dis Primers* 2016;2:16057.
5. Bozdag G, Mumusoglu S, Zengin D, et al. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. *Human reproduction* 2016;31(12):2841-55.
6. Zhuang J, Liu Y, Xu L, et al. Prevalence of the polycystic ovary syndrome in female residents of Chengdu, China. *Gynecologic and obstetric investigation* 2014;77(4):217-23.
7. Lauritsen MP, Bentzen JG, Pinborg A, et al. The prevalence of polycystic ovary syndrome in a normal population according to the Rotterdam criteria versus revised criteria including anti-Mullerian hormone. *Human reproduction* 2014;29(4):791-801.
8. Tehrani FR, Rashidi H, Khomami MB, et al. The prevalence of metabolic disorders in various phenotypes of polycystic ovary syndrome: a community based study in Southwest of Iran. *Reproductive biology and endocrinology : RB&E* 2014;12:89.
9. Carmina E, Campagna AM, Lobo RA. A 20-year follow-up of young women with polycystic ovary syndrome. *Obstetrics and gynecology* 2012;119(2 Pt 1):263-9.
10. Pinola P, Piltonen TT, Puurunen J, et al. Androgen Profile Through Life in Women With Polycystic Ovary Syndrome: A Nordic Multicenter Collaboration Study. *The Journal of clinical endocrinology and metabolism* 2015;100(9):3400-7.
11. Ogedegbe G. Labeling and hypertension: it is time to intervene on its negative consequences. *Hypertension* 2010;56(3):344-5.
12. Pickering TG. Now we are sick: labeling and hypertension. *Journal of clinical hypertension* 2006;8(1):57-60.
13. Nickel B, Barratt A, Copp T, et al. Words do matter: a systematic review on how different terminology for the same condition influences management preferences. *BMJ open* 2017;7(7):e014129.
14. Daan NM, Louwers YV, Koster MP, et al. Cardiovascular and metabolic profiles amongst different polycystic ovary syndrome phenotypes: who is really at risk? *Fertility and sterility* 2014;102(5):1444-51 e3.
15. Gibson-Helm M, Teede H, Dunaif A, et al. Delayed diagnosis and a lack of information associated with dissatisfaction in women with polycystic ovary syndrome. *The Journal of clinical endocrinology and metabolism* 2017:jc20162963.
16. Lizneva D, Kirubakaran R, Mykhalchenko K, et al. Phenotypes and body mass in women with polycystic ovary syndrome identified in referral versus unselected populations: systematic review and meta-analysis. *Fertility and sterility* 2016.